Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Advancing RMS Patients.

This is a 6-month, open-label, multi-center, single arm design, including 300 advancing RMS
patients, evaluating overall safety and tolerability profile when acutely converting to
siponimod from oral or injectable RMS DMT.

Key Inclusion Criteria:

1. Signed informed consent must be obtained prior to participation in the study.

2. Male or female aged 18 to 65 years (inclusive) at screening

3. Patients with advancing RMS as defined by the principal investigator

4. Prior history of relapsing MS (RMS), with or without progressive features, according
to the 2010 Revised McDonald or Lublin criteria (Lublin et al, 2013)

5. EDSS score of >2.0 to 6.5 (inclusive)

6. Having been continuously treated with oral or injectable RMS DMTs

Key Exclusion criteria:

1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive hCG laboratory test.

2. Patients with any medically unstable condition as determine by the investigator.

3. History of hypersensitivity to the study drug or to drugs of similar chemical classes.

Other protocol-defined inclusion/exclusion criteria may apply.